Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 [motesanib] Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Subjects With Advanced Cancer.

Next Previous
Trial Profile

An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 [motesanib] Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Subjects With Advanced Cancer.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Motesanib (Primary) ; Cisplatin; Gemcitabine; Panitumumab
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Amgen

    • Most Recent Events

    • 19 Mar 2014 The study design has been changed from single group assignment to parallel group assignment and primary endpoint has been changed from safety and efficacy to safety only as reported by ClinicalTrials.gov record.
    • 24 Mar 2009 Primary outcome amended as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Planned end date (Feb 2008) added as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top